Chapter 12: Reflections on a Research Style; Collaborating with Clinical Trials

Dr. Arlinghaus first explains some of his research approach, noting that he uses intuition and logic to attack a problem as if he peels back an onion. Next he talks about his contributions to clinical trials.He begins with trial to improve treatment of CML patients with Imatinib with period doses of a compound that would inhibit production of Janus kinase 2.He also talks about his work developing an assay to determine whether a patient is in remission or not based on the number of leukemia cells present.[The recorder is paused]Dr. Arlinghaus next sketches several other projects in progress: his collaboration with Dr. Xiaoyan Jian and her work on Janus kinase 2;his continued work on lipocalin 23p2 and host involvement in the spread of cancer;the role of BCR-ABL proteins in Janus Kinase 2 activation.He notes he is currently writing a proposal to extend current NCI grant funding after 2015 and explains that funding is much more competitive today.https://openworks.mdanderson.org/mchv_interviewchapters/1295/thumbnail.jp